Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1200 Summit Avenue, Suite 414 FORT WORTH TX 76102 |
Tel: | N/A |
Website: | https://sanaramedtech.com |
IR: | See website |
Key People | ||
Ronald T. Nixon Executive Chairman of the Board | Zachary B. Fleming Chief Executive Officer | Michael D. McNeil Chief Financial Officer | Jacob A. Waldrop Chief Operating Officer |
Business Overview |
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Sanara Medtech Inc revenues increased 42% to $65M. Net loss decreased 46% to $4.3M. Revenues reflect Soft tissue repair products segment increase of 32% to $54.8M, Bone fusion products segment increase from $4M to $10M. Lower net loss reflects Change in fair value of earnout liabilit decrease from $285K (expense) to $3.4M (income). |
Employees: | 107 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $288.24M as of Dec 31, 2023 |
Annual revenue (TTM): | $64.99M as of Dec 31, 2023 |
EBITDA (TTM): | -$0.54M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.30M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3.51M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $4.55M as of Dec 31, 2023 |
Shares outstanding: | 8,622,805 as of Mar 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |